Home - Products - Others - Other Targets - Cyanidin-3,5-O-diglucoside chloride

Cyanidin-3,5-O-diglucoside chloride

CAS No. 2611-67-8

Cyanidin-3,5-O-diglucoside chloride( —— )

Catalog No. M29125 CAS No. 2611-67-8

Cyanidin-3,5-O-diglucoside chloride has antioxidant activity. Cyanidin-3,5-O-diglucoside inhibits hyperbaric pressure-induced GLAST decrease and can be used in glaucoma studies.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 675 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cyanidin-3,5-O-diglucoside chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Cyanidin-3,5-O-diglucoside chloride has antioxidant activity. Cyanidin-3,5-O-diglucoside inhibits hyperbaric pressure-induced GLAST decrease and can be used in glaucoma studies.
  • Description
    Cyanidin-3,5-O-diglucoside chloride has antioxidant activity. Cyanidin-3,5-O-diglucoside inhibits hyperbaric pressure-induced GLAST decrease and can be used in glaucoma studies.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2611-67-8
  • Formula Weight
    646.98
  • Molecular Formula
    C27H31ClO16
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [Cl-].OC[C@H]1O[C@@H](Oc2cc3c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Biotin-MBP(94 - 102)

    Biotin-MBP(94 - 102)

  • Examorelin

    Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?

  • Fibrinogen-Binding P...

    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor.?Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin